MTN is excited to share that the DELIVER study has completed enrollment of the first group of 150 participants.

MTN is excited to share that the DELIVER study (MTN-042) of the dapivirine vaginal ring and Truvada as PrEP in pregnancy has completed enrollment of the first group of 150 participants who were 8-9 months pregnant when they joined the study. Provided there are no safety concerns, the study will proceed with enrolling the next group of participants who are 7-8 months pregnant.  DELIVER is a Phase IIIb open-label study being conducted in Malawi, South Africa and Uganda and Zimbabwe, and the first of the dapivirine vaginal ring, which was recently recommended for HIV prevention by the World Health Organization, in pregnancy.